𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Doxycycline sustained release from brushite cements for the treatment of periodontal diseases

✍ Scribed by Faleh Tamimi; Jesús Torres; Ruggero Bettini; Francesca Ruggera; Carmen Rueda; Manuel López-Ponce; Enrique Lopez-Cabarcos


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
474 KB
Volume
85A
Category
Article
ISSN
1549-3296

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Doxycycline (DOXY) is a wide spectrum antibiotic used in the treatment of dental, periodontal, and bone infections. Brushite cements are calcium phosphate biomaterials especially interesting for bone regeneration processes. In this work, we describe the preparation of a brushite cement containing DOXY and the drug release from the cement. DOXY solutions were mixed with the cement powder and after a 50% burst release in the first 12 h, a slow and controlled release was achieved over 3.5 days. The release of DOXY hyclate was controlled by both, diffusion and Ca^2+^ interaction. Formation of DOXY‐Ca^2+^ chelates was detected in the cement structure using solid state fluorescence. The brushite cement loaded with DOXY hyclate had antibacterial activity against periodontal pathogens: Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and Bacteroides frosthytus. This new biomaterial may be helpful for the treatment of periodontal diseases. © 2007 Wiley Periodicals, Inc. J Biomed Mater Res, 2008


📜 SIMILAR VOLUMES


Semisolid systems containing propolis fo
✍ Marcos L. Bruschi; David S. Jones; Heitor Panzeri; Maria P.D. Gremião; Osvaldo d 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB

Formulations containing poloxamer 407 (P407), carbopol 934P (C934P), and propolis extract (PE) were designed for the treatment of periodontal disease. Gelation temperature, in vitro drug release, rheology, hardness, compressibility, adhesiveness, mucoadhesion, and syringeability of formulations were

Sustained-release (+)-PHNO [MK-458 (HPMC
✍ Dr. Jesse M. Cedarbaum; Mary Clark; Linda H. Toy; Alison Green-Parsons 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 683 KB

## Abstract 4‐‐Propyl‐9‐hydroxynaphthoxazine, or MK‐458 (HPMC), a selective, nonergot D2 agonist administered orally twice a day in sustained‐release form, was studied as adjunctive therapy with carbidopa‐levodopa (Sinemet) in 12 Parkinson's disease patients with motor response fluctuations. The do